The CUI was created ( via expert input ) by weighing the relative benefit/risk of four components ( glycosylated hemoglobin [ HbA1c ] , percentage of patients with HbA1c 7 % , hypoglycemia rate , and time to steady-state dose ) ; individual utility values were multiplied to compute CUI values for LY1 and LY2 relative to GL , and bootstrap samples were used to determine variability .